Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2016 1
2017 1
2018 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE, da Silva Camacho AH, Miranda RL, Elias PCL, de Castro Musolino NR, Nazato D, Jallad R, Huayllas MKP, Mota JIS, Almeida T, Portes E, Ribeiro-Oliveira A, Vilar L, Boguszewski CL, Winter Tavares AB, Nunes-Nogueira VS, Mazzuco TL, Rech CGSL, Marques NV, Chimelli L, Czepielewski M, Bronstein MD, Abucham J, de Castro M, Kasuki L, Gadelha M. Wildemberg LE, et al. Among authors: nazato d. J Clin Endocrinol Metab. 2021 Jun 16;106(7):2047-2056. doi: 10.1210/clinem/dgab125. J Clin Endocrinol Metab. 2021. PMID: 33686418
gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Wildemberg LE, Henriques D, Elias PCL, Lima CHA, Musolino NRC, Camacho AHS, Faria O, Nazato D, Abucham J, Vilar L, Mota JI, Huayllas MKP, Chimelli L, Castro M, Kasuki L, Gadelha MR. Wildemberg LE, et al. Among authors: nazato d. Cancers (Basel). 2021 Sep 28;13(19):4857. doi: 10.3390/cancers13194857. Cancers (Basel). 2021. PMID: 34638340 Free PMC article.
Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event.
Casagrande A, Bronstein MD, Jallad RS, Moraes AB, Elias PC, Castro M, Czepielewski MA, Boschi A, Ribeiro-Oliveira A Jr, Schweizer JR, Vilar L, Nazato DM, Gadelha MR, Abucham J; all other investigators of the study. Casagrande A, et al. Among authors: nazato dm. Neuroendocrinology. 2017;104(3):273-279. doi: 10.1159/000446542. Epub 2016 May 5. Neuroendocrinology. 2017. PMID: 27161443 Free article.